Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of 18.48% is 835% above its 5-year average of 1.98%, near the high end of its 5-year range (-29.71%–22.21%).
10.88% above its 12-month average of 16.67%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): 18.51%.
EBITDA MARGIN
18.48%
EBITDA MARGIN AVG TTM
16.67%
EBITDA MARGIN AVG 3Y
8.03%
EBITDA MARGIN AVG 5Y
1.98%
EBITDA MARGIN AVG 10Y
-11.27%
EBITDA MARGIN AVG 15Y
-33.25%
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+10.88%
CURRENT VS 3Y AVG
+130.09%
CURRENT VS 5Y AVG
+835.13%
CURRENT VS 10Y AVG
+263.96%
CURRENT VS 15Y AVG
+155.59%
CURRENT VS 20Y AVG
N/A
Market Cap
$3.57B
EBITDA Margin
-174.74%
TTM Avg
-257.44%
3Y Avg
-315.29%
5Y Avg
-346.07%
Market Cap
$3.54B
EBITDA Margin
-4940.36%
TTM Avg
-4940.36%
3Y Avg
-3147.19%
5Y Avg
-1703.30%
Market Cap
$3.52B
EBITDA Margin
-1.38%
TTM Avg
-8.27%
3Y Avg
-15.09%
5Y Avg
-16.30%
Market Cap
$3.64B
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$3.48B
EBITDA Margin
-70.74%
TTM Avg
-2343.52%
3Y Avg
-1340.84%
5Y Avg
-951.82%
Market Cap
$3.44B
EBITDA Margin
-21676.57%
TTM Avg
-21676.57%
3Y Avg
-14888.43%
5Y Avg
-11379.97%
Market Cap
$3.38B
EBITDA Margin
10.88%
TTM Avg
18.32%
3Y Avg
-3.89%
5Y Avg
-19.05%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Veracyte, Inc. (VCYT) | $3.56B | 18.48% | 16.67% | 8.03% | 1.98% |
| Tango Therapeutics, Inc. (TNGX)vs › | $3.57B | -174.74% | -257.44% | -315.29% | -346.07% |
| Xenon Pharmaceuticals Inc. (XENE)vs › | $3.54B | -4940.36% | -4940.36% | -3147.19% | -1703.30% |
| iRhythm Technologies, Inc. (IRTC)vs › | $3.52B | -1.38% | -8.27% | -15.09% | -16.30% |
| Regencell Bioscience Holdings Limited (RGC)vs › | $3.64B | N/A | N/A | N/A | N/A |
| IDEAYA Biosciences, Inc. (IDYA)vs › | $3.48B | -70.74% | -2343.52% | -1340.84% | -951.82% |
| Celcuity Inc. (CELC)vs › | $3.47B | N/A | N/A | N/A | N/A |
| Pulse Biosciences, Inc. (PLSE)vs › | $3.44B | -21676.57% | -21676.57% | -14888.43% | -11379.97% |
| Acadia Pharmaceuticals Inc. (ACAD)vs › | $3.38B | 10.88% | 18.32% | -3.89% | -19.05% |
| Parabilis Medicines, Inc. (PBLS)vs › | $3.36B | N/A | N/A | N/A | N/A |
Gross Margin
72.1%
EBITDA Margin
18.5%
Operating Margin
17.0%
Net Margin
20.4%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | 18.51% |
| 2026-03-31 | 21.05% |
| 2025-12-31 | 22.21% |
| 2025-09-30 | 21.39% |
| 2025-06-30 | 0.17% |
| 2025-03-31 | 7.22% |
| 2024-12-31 | 8.79% |
| 2024-09-30 | 15.45% |
| 2024-06-30 | 9.04% |
| 2024-03-31 | 0.96% |
| 2023-12-31 | -29.71% |
| 2023-09-30 | -27.10% |
| 2023-06-30 | -1.32% |
| 2023-03-31 | -4.64% |
| 2022-12-31 | 1.41% |
| 2022-09-30 | -3.32% |
| 2022-06-30 | -5.82% |
| 2022-03-31 | -12.82% |
| 2021-12-31 | -8.81% |
| 2021-09-30 | -17.46% |
| 2021-06-30 | -5.40% |
| 2021-03-31 | -116.79% |
| 2020-12-31 | -17.51% |
| 2020-09-30 | -6.67% |
| 2020-06-30 | -43.92% |
| 2020-03-31 | -32.86% |
| 2019-12-31 | -23.26% |
| 2019-09-30 | -2.57% |
| 2019-06-30 | -7.22% |
| 2019-03-31 | -3.80% |
| 2018-12-31 | -10.83% |
| 2018-09-30 | -14.16% |
| 2018-06-30 | -21.66% |
| 2018-03-31 | -39.79% |
| 2017-12-31 | -29.48% |
| 2017-09-30 | -30.68% |
| 2017-06-30 | -30.78% |
| 2017-03-31 | -40.26% |
| 2016-12-31 | -18.65% |
| 2016-09-30 | -21.43% |
| 2016-06-30 | -65.10% |
| 2016-03-31 | -66.34% |
| 2015-12-31 | -54.72% |
| 2015-09-30 | -66.82% |
| 2015-06-30 | -70.79% |
| 2015-03-31 | -64.19% |
| 2014-12-31 | -63.26% |
| 2014-09-30 | -76.43% |
| 2014-06-30 | -72.42% |
| 2014-03-31 | -84.42% |
| 2013-12-31 | -80.14% |
| 2013-09-30 | -103.90% |
| 2013-06-30 | -102.33% |
| 2013-03-31 | -129.93% |
| 2012-12-31 | -110.75% |
| 2012-09-30 | -147.70% |
